As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...